Ipsen News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

08.08.17	IPSEN: Disclosure of transactions in own shares between 31/07/2017 and 04/08/2017 (Businesswire)
01.08.17	IPSEN: Disclosure of Transactions in Own Shares Between 24/07/2017 and 28/07/2017 (Businesswire)
25.07.17	IPSEN: Disclosure of transactions in own shares between 17/07/2017 and 21/07/2017 (Businesswire)
18.07.17	IPSEN: Disclosure of transactions in own shares between 10/07/2017 and 14/07/2017 (Businesswire)
18.07.17	Half-year IPSEN liquidity contract statement entered into with NATIXIS (Businesswire)
03.07.17	Ipsen: Somatuline® Autogel® 120 mg Receives Japanese Approval for a New Indication for the Treatment of Gastro-Entero-Pancreatic Neuroendocrine Tumors (Businesswire)
16.06.17	Ipsen Announces FDA Approval of Dysport® (Abobotulinumtoxina) for the Treatment of Lower Limb Spasticity in Adults (Businesswire)
08.06.17	Ipsen initiates share buy-back program to cover its free performance share allocation plan (Businesswire)
01.06.17	IPSEN: Description of the regulatory framework of the share repurchase program proposed by the Board of Directors to the approval of the Combined Shareholders’ Meeting to be held on 7 June 2017 (Businesswire)
14.04.17	Ipsen Appoints Dr. Alexandre Lebeaut as Executive Vice-President, R&D, and Chief Scientific Officer (Businesswire)
10.03.17	Ipsen: Monthly information regarding the total number of voting rights and total number of shares of the Company (Businesswire)
02.03.17	Ipsen Appoints Benoit Hennion as Executive Vice President and President, Primary Care (Businesswire)
10.01.17	IPSEN: Monthly Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company (Businesswire)
21.12.16	Exelixis and Ipsen amend exclusive licensing agreement for the commercialization and development of cabozantinib to include Canada (Businesswire)
13.12.16	Ipsen Announces Its Corporate Agenda for 2017 (Businesswire)
09.12.16	Ipsen: Monthly Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company (Businesswire)
22.11.16	IPSEN: Disclosure of transactions in own shares between 14/11/2016 and 18/11/2016 (Businesswire)
15.11.16	IPSEN: Disclosure of Transactions in Own Shares between 07/11/2016 and 11/11/2016 (Businesswire)
10.11.16	Ipsen: Monthly information regarding the total number of voting rights and total number of shares of the Company (Businesswire)
08.11.16	IPSEN: Disclosure of Transactions in Own Shares between 31/10/2016 and 04/11/2016 (Businesswire)
01.11.16	IPSEN: Disclosure of Transactions in Own Shares between 10/24/2016 and 10/28/2016 (Businesswire)
26.10.16	Ipsen Reports 12.2%1 Sales Growth for the Third Quarter of 2016 and Raises Full Year Guidance (Businesswire)
25.10.16	IPSEN: Disclosure of transactions in own shares between 17/10/2016 and 21/10/2016 (Businesswire)
10.10.16	Ipsen: Monthly information regarding the total number of voting rights and total number of shares of the Company (Businesswire)
27.09.16	Ipsen Announces Data Presentations of Cabozantinib (Cabometyx™), Lanreotide (Somatuline® Autogel®) and Telotristat Ethyl* at the European Society for Medical Oncology (ESMO) 2016 Congress (Businesswire)
09.09.16	Ipsen: Monthly Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company (Businesswire)
08.08.16	Ipsen: Monthly Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company (Businesswire)
01.08.16	Ipsen Announces FDA Approval of Dysport® (abobotulinumtoxinA) for Injection for the Treatment of Lower Limb Spasticity in Children Aged Two and Older (Businesswire)
22.07.16	Ipsen and its Partner Exelixis Receive Positive CHMP Opinion for Cabometyx™ (Cabozantinib) for the Treatment of Advanced RCC in Adults Following Prior VEGF-Targeted Therapy (Businesswire)
11.07.16	David Meek appointed as Chief Executive Officer of Ipsen (Businesswire)
08.07.16	Half-Year IPSEN Liquidity Contract Statement Entered into with NATIXIS (Businesswire)
08.07.16	Ipsen: Monthly Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company (Businesswire)
27.06.16	Ipsen initiates a new share buy-back program to cover its free performance share allocation plan (Businesswire)
09.06.16	Ipsen Successfully Issues Inaugural €300 Million 7-Year Notes (Businesswire)
07.06.16	Ipsen: Monthly Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company (Businesswire)
06.06.16	The Ipsen Group Launches an Employee Shareholding Plan (Businesswire)
31.05.16	Combined Shareholders’ Meeting of IPSEN S.A. held on 31 May 2016 (Businesswire)
27.05.16	IPSEN: Description of the Regulatory Framework of the Share Repurchase Program Proposed by the Board of Directors to the Approval of the Combined Shareholders’ Meeting to Be Held on 31 May 2016 (Businesswire)
10.05.16	Ipsen: Combined Shareholders’ Meeting of 31 May 2016 (Businesswire)
10.05.16	Ipsen: Monthly Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company (Businesswire)
03.05.16	Oncodesign and Ipsen Enter into a Strategic Partnership in Oncology and Oncodesign Joins Ipsen’s Paris-Saclay Campus (Businesswire)
28.04.16	Ipsen’s First Quarter 2016 Sales (Businesswire)
26.04.16	Probi and Ipsen Sign Extensive Primary Care Distribution Agreement for Probiotic LP299V®, Lactobacillus plantarum 299v (Businesswire)
08.04.16	Ipsen: Monthly Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company (Businesswire)
05.04.16	Dassault Systèmes and Ipsen sign collaborative agreement to develop innovative programs to support Ipsen’s drug discovery (Businesswire)
31.03.16	The Ipsen Group Publishes Its 2015 Registration Document (Businesswire)
07.03.16	Ipsen: Monthly Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company (Businesswire)
07.03.16	Ipsen: Information Relating to the Compensation of Executive Directors (Businesswire)
01.03.16	Ipsen’s 2015 Results and 2016 Financial Objectives (Businesswire)
01.03.16	Exelixis and Ipsen Enter into Exclusive Licensing Agreement to Commercialize and Develop Novel Cancer Therapy Cabozantinib in Regions Outside the United States, Canada and Japan (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Logitech Intl	74.30	1.53 %	K V
Holcim	87.38	1.49 %	K V
Roche Hldg G	251.00	1.46 %	K V
Swiss Re	130.35	1.44 %	K V
UBS Group	27.07	1.35 %	K V
Swisscom	501.00	0.52 %	K V
Lonza Grp	532.40	0.26 %	K V
Nestle	74.08	0.14 %	K V
Sonova Hldg	295.60	0.00 %	K V
Geberit	512.20	-0.39 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Ipsen

Aktien Top/Flop

Meistgelesene Nachrichten